TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33573674

Group type: EXPERIMENTAL
Intervention: MATCH-ADTC (modular psychological intervention) plus usual care
Number of subjects: 334

Group type: COMPARATOR
Intervention: Assessment-enhanced usual care
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: MATCH-ADTC plus usual care
Number of subjects: 334
Study: 35963274

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 (5 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 33144221

Group type: EXPERIMENTAL
Intervention: [11C]raclopride
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: [11C]FLB 457
Number of subjects: 16
Study: 34851810

Group type: EXPERIMENTAL
Intervention: Ten-session group intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 34461058

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (Oxygen, n = 26)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CPAP (n = 40)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No treatment (Air; n = 26)
Number of subjects: 52
Study: 34264775

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 108
Study: 32935460

Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Solriamfetol 900 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 32719868

Group type: EXPERIMENTAL
Intervention: Vadadustat 150 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Vadadustat 300 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Vadadustat 600 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Vadadustat (all doses)
Number of subjects: 111
Study: 35979054

Group type: EXPERIMENTAL
Intervention: Esketamine (0.5 mg/kg + 2 ml normal saline)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 138
Study: 34171091

Group type: EXPERIMENTAL
Intervention: Type II diabetes mellitus (T2D)
Number of subjects: 898130

Group type: EXPERIMENTAL
Intervention: T2D as a mediator
Number of subjects: 898130
Study: 32920242

Group type: EXPERIMENTAL
Intervention: High intensity surveillance (Fukuoka guidelines)
Number of subjects: 4606

Group type: COMPARATOR
Intervention: Low intensity surveillance (AGA guidelines)
Number of subjects: 4606
Study: 34427295

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17134
Study: 35022058

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) combined with routine nursing
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine nursing (Control)
Number of subjects: 98
Study: 32725529

Group type: EXPERIMENTAL
Intervention: Free-range group (shoulder range exercises until limited by pain or wound dehiscence)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Limited-range group (shoulder movement restriction at 90° until 30 days after surgery)
Number of subjects: 60
Study: 35443830

Group type: EXPERIMENTAL
Intervention: 200 mg dose of the COMT inhibitor tolcapone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 33743059

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RALP)
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (RRP)
Number of subjects: 2650
Study: 32474206

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 4500
Study: 35811435

Group type: COMPARATOR
Intervention: Guided bone regeneration (GBR) using a 1:1 mixture of particulate autogenous bone and anorganic bovine bone mineral (ABBM) covered with native collagen membrane
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sticky bone using autologous fibrin glue (AFG) mixed with particulate autogenous bone and ABBM covered by concentrated growth factor (CGF) membrane
Number of subjects: 28
Study: 32892660

Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inotersen
Number of subjects: 0
Study: 34626573

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: As-needed ranibizumab
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Monthly bevacizumab
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: As-needed bevacizumab
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group (no SMH)
Number of subjects: 605
Study: 34193179

Group type: EXPERIMENTAL
Intervention: Real non-invasive brain stimulation (NIBS; real tDCS + iTBS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham non-invasive brain stimulation (NIBS; sham tDCS + iTBS)
Number of subjects: 24
Study: 36422763

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 329

Group type: COMPARATOR
Intervention: Adjuvant concurrent chemoradiotherapy (CCRT)
Number of subjects: 329
Study: 36137630

Group type: EXPERIMENTAL
Intervention: Activity enabling uniform intervention (shorts, polo shirt, and sports shoes) provided to students, including two additional sports shirts and one pair of shorts.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Activity enabling uniform intervention (shorts, polo shirt, and sports shoes).
Number of subjects: 24
Study: 33028557

Group type: EXPERIMENTAL
Intervention: Standardised ergonomics and posture training (10 weeks, once a week for 20-30 min)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Back-fitness training (12 weeks, once a week for 45-60 min)
Number of subjects: 700
Study: 36179810

Group type: EXPERIMENTAL
Intervention: COMT Val homozygotes group
Number of subjects: 60

Group type: COMPARATOR
Intervention: COMT Met-carrier group
Number of subjects: 60

Group type: COMPARATOR
Intervention: DRD2/ANKK1 and BDNF polymorphisms
Number of subjects: 60
Study: 34022150

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1·4 mg/m2, prednisone 100 mg) every 21 days for up to six cycles
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 37
Study: 32769884

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (sham rTMS)
Number of subjects: 103
Study: 36476738

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair without acromioplasty
Number of subjects: 86

Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair with acromioplasty
Number of subjects: 86
Study: 34357009

Group type: EXPERIMENTAL
Intervention: 4000 m altitude condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2000 m altitude condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All conditions (independent of altitude)
Number of subjects: 12
Study: 36263382

Group type: EXPERIMENTAL
Intervention: HF-ESWT (Group A)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 153
Study: 34013579

Group type: EXPERIMENTAL
Intervention: Transitional Care Program (TCP) plus routine care
Number of subjects: 104

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 104
Study: 34802700

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 µg/kg/h)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 76
Study: 34496836

Group type: EXPERIMENTAL
Intervention: SoC + bezlotoxumab
Number of subjects: 10

Group type: COMPARATOR
Intervention: SoC
Number of subjects: 10
Study: 32118765

Group type: COMPARATOR
Intervention: Commercial kit (25mm penetrating length)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Shorter needle (20mm penetrating length)
Number of subjects: 45
Study: 34695800

Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution (specific dosage and duration not mentioned)
Number of subjects: 6107

Group type: EXPERIMENTAL
Intervention: Improved latrine use by the household
Number of subjects: 6107
Study: 32717058

Group type: EXPERIMENTAL
Intervention: Oral D/L-3-Hydroxybutyrate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matched intravenous D/L-3-Hydroxybutyrate
Number of subjects: 8
Study: 35830550

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100, 300, 400, or 500 U with hydrogel admixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with hydrogel admixture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA + hydrogel treatment groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA + hydrogel admixture
Number of subjects: 0
Study: 33472353

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lactic acid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Not sure
Number of subjects: 16
Study: 35291965

Group type: EXPERIMENTAL
Intervention: Cisplatin and 5 fluorouracil (CF) followed by docetaxel (D)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cisplatin and 5 fluorouracil (CF) followed by docetaxel (D) + radiotherapy (RT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cisplatin and 5 fluorouracil (CF)
Number of subjects: 116
Study: 35508968

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs prioritising small sample size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs prioritising high power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs applied to real-world ANZ 9311 data
Number of subjects: 0
Study: 32507146

Group type: EXPERIMENTAL
Intervention: TMJ manual therapy plus exercise therapy in addition to routine physiotherapy for neck pain (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine physiotherapy for neck pain (Group A)
Number of subjects: 40
Study: 35393165

Group type: EXPERIMENTAL
Intervention: venlafaxine XR for 12 weeks
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: augmentation with aripiprazole for 12 additional weeks
Number of subjects: 468

Group type: COMPARATOR
Intervention: placebo for 12 additional weeks
Number of subjects: 468
Study: 34269376

Group type: EXPERIMENTAL
Intervention: CTCA with selective FFRCT (experimental group)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Standard clinical care pathways (standard group)
Number of subjects: 1400
Study: 32108304

Group type: EXPERIMENTAL
Intervention: OurRelationship and ePREP interventions
Number of subjects: 742

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 742
Study: 33866946

Group type: EXPERIMENTAL
Intervention: Omeprazole for 6 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study: 34645842

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 490 m
Number of subjects: 32
Study: 35791477

Group type: EXPERIMENTAL
Intervention: Post-discharge pharmacist-led follow-up (weekly for 6 months)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Routine medication guidance (control group)
Number of subjects: 125
Study: 32316870

Group type: EXPERIMENTAL
Intervention: Passive + Active Heat (PAH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active Heat (AH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study: 34290063

Group type: EXPERIMENTAL
Intervention: Peer mentorship intervention (up to eight community-based self-management support sessions delivered by a peer mentor)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (information resources)
Number of subjects: 50
Study: 32135488

Group type: EXPERIMENTAL
Intervention: Exposure therapy with Tegenaria Domestica (domestic house spider)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control condition with Dendrobaena Veneta/Eisenaia hortensis (red earthworm)
Number of subjects: 37
Study: 35116067

Group type: EXPERIMENTAL
Intervention: Guilingji capsules (GLJC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ginkgo extract tablets
Number of subjects: 96
Study: 33190679

Group type: EXPERIMENTAL
Intervention: Levetiracetam (40 mg/kg)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Phenytoin (20 mg/kg)
Number of subjects: 286
Study: 34875556

Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit
Number of subjects: 741

Group type: COMPARATOR
Intervention: Written reminder
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: HPV positive women referred to colposcopy
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Histopathological confirmation
Number of subjects: 741
Study: 34701328

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy + cisplatin concurrent radiochemotherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: PF adjuvant chemotherapy + cisplatin concurrent radiochemotherapy
Number of subjects: 72
Study: 32105658

Group type: EXPERIMENTAL
Intervention: PlaqueHD toothpaste
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 616279865

Group type: EXPERIMENTAL
Intervention: NRB-Flush (non-rebreather mask with flush rate oxygen >40 L/min)
Number of subjects: 27

Group type: COMPARATOR
Intervention: aBVM-Flush (assisted bag-valve-mask with flush rate oxygen)
Number of subjects: 27

Group type: COMPARATOR
Intervention: NRB-Flush vs aBVM-Flush
Number of subjects: 27
Study: 35568246

Group type: EXPERIMENTAL
Intervention: Escalated dose RT (EDRT; 70.2 Gy/39 fractions/5 days a week)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard dose RT (SDRT; 55.8 Gy/31 fractions/5 days a week)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Escalated dose RT (EDRT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard dose RT (SDRT)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 95
Study: 33200303

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (S-1 plus cisplatin) followed by D2 gastrectomy plus adjuvant chemotherapy with S-1 (Arm B)
Number of subjects: 316

Group type: COMPARATOR
Intervention: D2 surgery followed by adjuvant chemotherapy with S-1 (Arm A)
Number of subjects: 316
Study: 33042004

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic Diet (VLCKD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard Low-Calorie Diet (LC)
Number of subjects: 39
Study: 33811761

Group type: EXPERIMENTAL
Intervention: Velusetrag 30 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Velusetrag 5 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Velusetrag 15 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 34252122

Group type: EXPERIMENTAL
Intervention: Writing a narrative text about a fictional person
Number of subjects: 0

Group type: COMPARATOR
Intervention: Writing about an unrelated topic
Number of subjects: 0
Study: 32473020

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate 400mg twice daily on Day 1, then 400mg once daily from Day 2 to Day 10
Number of subjects: 0
Study: 33527859

Group type: EXPERIMENTAL
Intervention: PACE-Life walking intervention
Number of subjects: 16
Study: 33947726

Group type: EXPERIMENTAL
Intervention: Pictorial support (PicPecc)
Number of subjects: 0
Study: 93204632

Group type: EXPERIMENTAL
Intervention: Interferon alfa (3 million units three times weekly)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interferon alfa (3 million units three times weekly) after prednisolone withdrawal
Number of subjects: 48

Group type: COMPARATOR
Intervention: Spontaneous ALT normalization
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients with prednisolone pretreatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Patients without prednisolone pretreatment
Number of subjects: 48
Study: 35438151

Group type: EXPERIMENTAL
Intervention: Vicagrel 20/5 mg (LD/MD)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Vicagrel 24/6 mg
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Vicagrel 30/7.5 mg
Number of subjects: 279

Group type: COMPARATOR
Intervention: Clopidogrel 300/75 mg
Number of subjects: 279
Study: 34285350

Group type: EXPERIMENTAL
Intervention: Decipher Biopsy testing
Number of subjects: 855
Study: 32035053

Group type: EXPERIMENTAL
Intervention: CaniLeishÂ® vaccine, n = 85
Number of subjects: 168
Study: 35830649

Group type: EXPERIMENTAL
Intervention: A+AVD
Number of subjects: 1334

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 1334
Study: 34223754

Group type: EXPERIMENTAL
Intervention: Lymphatic drainage kinesis‐taping
Number of subjects: 33

Group type: COMPARATOR
Intervention: Complex treatment including lymphatic drainage kinesis‐taping and low-frequency pulse magnetic therapy
Number of subjects: 33
Study: 32279471

Group type: EXPERIMENTAL
Intervention: Standard modified Epley maneuver (mEpley)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Modified Epley maneuver with a pillow under the shoulders (mEpley‐PS)
Number of subjects: 41
Study: 34259826

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 50
Study: 33745865

Group type: EXPERIMENTAL
Intervention: Veliparib (120 mg twice daily) during chemoradiotherapy (CRT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo during chemoradiotherapy (CRT)
Number of subjects: 52
Study: 35092305

Group type: EXPERIMENTAL
Intervention: KY1005 (0.006, 0.018, 0.05, 0.15, 0.45, 1.35, 4, or 12 mg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: KY1005 (0.45 mg/kg and above)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: KY1005
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33833182

Group type: COMPARATOR
Intervention: Private aesthetic surgeons
Number of subjects: 145

Group type: COMPARATOR
Intervention: Private ASAPS surgeons (n = 126)
Number of subjects: 145
Study: 35615229

Group type: EXPERIMENTAL
Intervention: ProximaTM point of care device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard ABG sampling system
Number of subjects: 20
Study: 32741143

Group type: EXPERIMENTAL
Intervention: Low-dose Methotrexate (target dose 15-20 mg/week)
Number of subjects: 4786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4786
Study: 35923827

Group type: EXPERIMENTAL
Intervention: CDP-choline (Rischiaril® Forte, 1,000 mg of citicoline sodium salt)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment (control group - CG)
Number of subjects: 30
Study: 33373492

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 28
Study: 35020019

Group type: EXPERIMENTAL
Intervention: Treat and Extend (T&E) regimen
Number of subjects: 124

Group type: COMPARATOR
Intervention: Pro Re Nata (PRN) regimen
Number of subjects: 124
Study: 33819066

Group type: EXPERIMENTAL
Intervention: Budesonide orodispersible tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34351504

Group type: EXPERIMENTAL
Intervention: PBM imitation + toothpaste with SA8% (G2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PBM + toothpaste with SA8% (G4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PBM imitation + toothpaste with no active ingredient (G1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PBM + toothpaste without the active ingredient (G3)
Number of subjects: 80
Study: 33529620

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32048131

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) intravenously for 72 hours (150 mg/kg/h for 1 hour, followed by 12.5 mg/kg/h for 4 hours, followed by 6.25 mg/kg for 67 hours)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) intravenously for 72 hours
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 214
Study: 33587403

Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (700 mg) + Lisdexamfetamine (50 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lisdexamfetamine (50 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Viloxazine extended-release (700 mg)
Number of subjects: 36
Study: 35063243

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg per day for 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (starch for 24 weeks)
Number of subjects: 60
Study: 32998018

Group type: EXPERIMENTAL
Intervention: Additional online management
Number of subjects: 309

Group type: COMPARATOR
Intervention: Routine clinical prenatal care
Number of subjects: 309
Study: 35987546

Group type: EXPERIMENTAL
Intervention: Telephone-based Behavioral Activation (BA) intervention, eight weekly individual sessions
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 71
Study: 32097450

Group type: EXPERIMENTAL
Intervention: Whole-grain rye diet (± SDG supplements)
Number of subjects: 40
Study: 35899230

Group type: EXPERIMENTAL
Intervention: Mustard (MU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ginger (GI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Warm water (WA)
Number of subjects: 18
Study: 32033227

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (evidence-based brochure, phone counseling, mailed reminders, and communications with primary care providers)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Low-intensity intervention (brochure only)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Low-intensity intervention
Number of subjects: 178
Study: 34154965

Group type: EXPERIMENTAL
Intervention: Topical application of black pepper essential oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: No extra interventions (Control group)
Number of subjects: 60
Study: 33633233

Group type: EXPERIMENTAL
Intervention: Catvira (epigallocatechingallate + sofosbuvir + ribavirin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin
Number of subjects: 80